IGF is DANGEROUS!!???

[RONJON]

ive been reading on here that alot of people are saying that taking IGF can cause cancer or at least speed its progression!!! Well are u guys continuing to take it for PCT because i have began to think that IGF was a necessity for PCT along with HCG and either nolva or clomid...

if u guys are ANTI-IGF now then what could i substitute for it during PCT???

RJ

 

[Bobaslaw]

IGF-1 as well as HGH does not cause cancer, but it can increase existing cancerous cells/tissues.
This is because IGF can bind and activate cancer cell receptors just like it does for myoblasts, signaling to proliferate/differentiate.
The most responsible thing to do is to understand this as well as to be up to date with all medical physicals/screenings. If you have or have had or even suspect any cancer, definitely do not use.


Take Care...

 

[2BIGFRED]

IGF-1 as well as HGH does not cause cancer, but it can increase existing cancerous cells/tissues.
This is because IGF can bind and activate cancer cell receptors just like it does for myoblasts, signaling to proliferate/differentiate.
The most responsible thing to do is to understand this as well as to be up to date with all medical physicals/screenings. If you have or have had or even suspect any cancer, definitely do not use.


Take Care...

What about in cases like mine and Baldnazis were we didnt have cancer but a tumor and got it removed.Now they checked my tumor and it was negative for cancer.They told me I had nothing to worry about that no traces of cancer was found in my tumor.Would it be safe for me to use igf sometimes in the future or gh in the future??

 

[GoneForever]

ive been reading on here that alot of people are saying that taking IGF can cause cancer or at least speed its progression!!! Well are u guys continuing to take it for PCT because i have began to think that IGF was a necessity for PCT along with HCG and either nolva or clomid...

if u guys are ANTI-IGF now then what could i substitute for it during PCT???

RJ

There have been some reports but no more in people who get cancer from "diet soda" or "tin foil",etc... I take my chances by the majority. If you got 10's of thousands of people using igf for a long time, how many cases have you heard of? Go by those odds imo.

 

[2BIGFRED]

There have been some reports but no more in people who get cancer from "diet soda" or "tin foil",etc... I take my chances by the majority. If you got 10's of thousands of people using igf for a long time, how many cases have you heard of? Go by those odds imo.

Thats the problem I have is they say everything gives you cancer.

 

[Bobaslaw]

Umm, you have to have cancer 1st, before IGF will accelerate its proliferation... Thats the difference between "getting cancer" and "proliferating existing cancer". IGF does not "cause" cancer, it just activates receptors on cancer cells, telling them to do the same thing it does for myoblasts (muscle stem cells). Yes, we want myoblasts to proliferate and differentiate (hyperplasia) obviously, but not cancer cells.

Your body produces IGF naturally and it does not give iteslf cancer because of this. However, people with high levels of GH/IGF are prone to have existing cancers spread more quickly.

Personally, If I knew i have had any tumor growth or was prone to such, I would not risk it because tumors are affected by IGF.

Take Care,
Bob

 

[GoneForever]

^^^ exactly. Plus, I think it would take a VERY large amount of IGF over a very long time to accelerate the cancer any faster than you probably would have eventually gotten it anyway.

 

[pesty4077]

For all of you worried about getting cancer with growth, there is a simple test your doctor can give you to determined if you have that potential.

 

[scott123456789]

You guys are 100 % correct. I have had this confirmed by the Pathologists of all the Hosptials I work at (I service the Lab equipment). It should be alegal as far as I am concerned . Perhaps a diclaimer like on cigarettes. It will say that if you have preexisting cancer the IGF-1 will potentially make the cancer spread more quickly. I forgot. There is a study at one reseach place that said IGF-1 may slow breast cancer in woman.

 

[rotty]

You would probably want to talk to an endocrinologist that is cool

 

[guns123]

apparantly ther are quite a few people who hava cancer but it is dormant or does not grow at a rate to be worried about.

gh and igf would cause this to grow tho

 

[dragonfire101]

**broken link removed**

I have posted studies on here in the past if you do a search that IGF-1 can promote and increase cancer risk even if you already don't have cancer.

 

[dragonfire101]

Umm, you have to have cancer 1st, before IGF will accelerate its proliferation... Thats the difference between "getting cancer" and "proliferating existing cancer". IGF does not "cause" cancer, it just activates receptors on cancer cells, telling them to do the same thing it does for myoblasts (muscle stem cells).

IGF-1 can cause antiapoptotic effects that make non cancerous cells cancerous, which then proliferates those cells into a hyperproliferation, which in turn can precede with the formation of an adenoma(tumor)

"The end results of these opposing effects of IGF-1 may be several-fold. First, there is increased proliferation and thus epithelial cell turnover within tissues. Second, the antiapoptotic effects cause an imbalance in the usual tight control between proliferation and cell death and result in hyperproliferation. This is the first stage in the development of many cancers and has been particularly well demonstrated in colorectal tumorigenesis in which it precedes the formation of colonic adenomas. Third, such an imbalance between cell proliferation and death would favour, even slightly, survival of stem cells that had undergone early genetic 'hits'.[4] This would increase the pool of damaged cells available for second and subsequent hits. Higher levels of IGF-1 would be expected to activate survival pathways that would make programmed cell death of damaged cells slightly less probable. When applied overall to a large number of 'at risk' cells over many years, even a small influence in favour of survival of such cells could accelerate carcinogenesis, although not initiate cancer development per se."




References

1. Le Roith, D., Bondy, C., Yakar, S., Liu, J.L. & Butler, A. (2001) The somatomedin hypothesis: 2001. Endocrine Reviews, 22, 53–74.
2. Laban, C., Bustin, S.A. & Jenkins, P.J. (2002) The GH-IGF-I axis and breast cancer. Trends in Endocrinology and Metabolism, 14, 28–34.
3. Bustin, S.A. & Jenkins, P.J. (2001) The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends in Molecular Medicine, 7, 447–454.
4. Pollak, M.N., Schernhammer, E.S. & Hankinson, S.E. (2004) Insulin-like growth factors and neoplasia. Nature Reviews Cancer, 4, 505–518.
5. Tornell, J., Carlsson, B., Pohjanen, P., Wennbo, H., Rymo, L. & Isaksson, O. (1992) High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. Journal of Steroid Biochemistry and Molecular Biology, 43, 237–242.
6. Bates, P., Fisher, R., Ward, A., Richardson, L., Hill, D.J. & Graham, C.F. (1995) Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). British Journal of Cancer, 72, 1189–1193.
7. Yang, X.F., Beamer, W.G., Huynh, H. & Pollak, M. (1996) Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Research, 56, 1509–1511.
8. Arteaga, C.L., Kitten, L.J., Coronado, E.B., Jacobs, S., Kull, F.C. Jr, Allred, D.C. & Osborne, C.K. (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. Journal of Clinical Investigation, 84, 1418–1423.
9. Pollak, M., Blouin, M.J., Zhang, J.C. & Kopchick, J.J. (2001) Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer, 85, 428–430.
10. Wu, Y., Yakar, S., Zhao, L., Hennighausen, L. & LeRoith, D. (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research, 62, 1030–1035.
11. Wu, Y., Cui, K., Miyoshi, K., Hennighausen, L., Green, J.E., Setser, J., LeRoith, D. & Yakar, S. (2003) Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Research, 63, 4384–4388.
12. Bustin, S.A., Dorudi, S., Phillips, S.M., Feakins, R.M. & Jenkins, P.J. (2002) Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biology, 23, 130–138.
13. Sachdev, D., Hartell, J.S., Lee, A.V., Zhang, X. & Yee, D. (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. Journal of Biological Chemistry, 5017–5024.
14. Gunnell, D.J., Smith, G.D., Frankel, S.J., Kemp, M. & Peters, T.J. (1998) Socio-economic and dietary influences on leg length and trunk length in childhood: a reanalysis of the Carnegie (Boyd Orr) survey of diet and health in prewar Britain (1937–39). Paediatrics and Perinatal Epidemiology, 12, 96–113.
15. De Stavola, B.L., dos Santos Silva I, McCormack, V., Hardy, R.J., Kuh, D.J. & Wadsworth, M.E. (2004) Childhood growth and breast cancer. American Journal of Epidemiology, 159, 671–682.
16. Stevenaert, A. & Beckers, A. (1996) Presurgical Octreotide: treatment in acromegaly. Metabolism, 45, 72–74.
17. Ahlgren, M., Melbye, M., Wohlfahrt, J. & Sorensen, T.I. (2004) Growth patterns and the risk of breast cancer in women. New England Journal of Medicine, 351, 1619–1626.
18. Gunnell, D., Okasha, M., Smith, G.D., Oliver, S.E., Sandhu, J. & Holly, J.M. (2001) Height, leg length, and cancer risk: a systematic review. Epidemiology Reviews, 23, 313–342.
19. Shalet, S.M., Clayton, P.E. & Price, D.A. (1988) Growth and pituitary function in children treated for brain tumours or acute lymphoblastic leukaemia. Hormone Research, 30, 53–61.
20. Taback, S.P. & Dean, H.J. (1996) Mortality in Canadian children with growth hormone (GH) deficiency receiving GH therapy 1967–1992. The Canadian Growth Hormone Advisory Committee. Journal of Clinical Endocrinology and Metabolism, 81, 1693–1696.
21. Swerdlow, A.J., Reddingius, R.E., Higgins, C.D., Spoudeas, H.A., Phipps, K., Qiao, Z., Ryder, W.D., Brada, M., Hayward, R.D., Brook, C.G., Hindmarsh, P.C. & Shalet, S.M. (2000) Growth hormone treatment of children with brain tumors and risk of tumor recurrence. Journal of Clinical Endocrinology and Metabolism, 85, 4444–4449.
22. Sklar, C.A., Mertens, A.C., Mitby, P., Occhiogrosso, G., Qin, J., Heller, G., Yasui, Y. & Robison, L.L. (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. Journal of Clinical Endocrinology and Metabolism, 87, 3136–3141.
23. Neglia, J.P., Friedman, D.L., Yasui, Y., Mertens, A.C., Hammond, S., Stovall, M., Donaldson, S.S., Meadows, A.T. & Robison, L.L. (2001) Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. Journal of National Cancer Institute, 93, 618–629.
24. Wada, E., Murata, M. & Watanabe, S. (1989) Acute lymphoblastic leukemia following treatment with human growth hormone in a boy with possible preanemic Fanconi's anemia. Japanese Journal of Clinical Oncology, 19, 36–39.
25. Gotherstrom, G., Svensson, J., Koranyi, J., Alpsten, M., Bosaeus, I., Bengtsson, B. & Johannsson, G. (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. Journal of Clinical Endocrinology and Metabolism, 86, 4657–4665.
26. Attanasio, A.F., Bates, P.C., Ho, K.K., Webb, S.M., Ross, R.J., Strasburger, C.J., Bouillon, R., Crowe, B., Selander, K., Valle, D. & Lamberts, S.W. (2002) Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status – 3-year results from the HypoCCS database. Journal of Clinical Endocrinology and Metabolism, 87, 1600–1606.
27. Monson, J.P. (2003) Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology, 148 Suppl 2, S9–14.
28. Swerdlow, A.J., Higgins, C.D., Adlard, P. & Preece, M.A. (2002) Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet, 360, 273–277.
29. Sperling, M.A., Saenger, P.H., Ray, H., Tom, W. & Rose, S.R. (2002) Growth hormone treatment and neoplasia: coincidence or consequence? Journal of Clinical Endocrinology and Metabolism, 87, 5351–5352.
30. Emerman, J.T., Leahy, M., Gout, P.W. & Bruchovsky, N. (1985) Elevated growth hormone levels in sera from breast cancer patients. Hormone and Metabolic Research, 17, 421–424.
31. Peyrat, J.P., Bonneterre, J., Hecquet, B., Vennin, P., Louchez, M.M., Fournier, C., Lefebvre, J. & Demaille, A. (1993) Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. European Journal of Cancer, 29A, 492–497.
32. Giovannucci, E., Pollak, M.N., Platz, E.A., Willett, W.C., Stampfer, M.J., Majeed, N., Colditz, G.A., Speizer, F.E. & Hankinson, S.E. (2000) A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiology, Biomarkers & Prevention, 9, 345–349.
33. Hankinson, S.E., Willett, W.C., Colditz, G.A., Hunter, D.J., Michaud, D.S., Deroo, B., Rosner, B., Speizer, F.E. & Pollak, M. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351, 1393–1396.
34. Ma, J., Pollak, M., Giovannucci, E., Chan, J.M., Tao, Y. & Hennekens, C.H. (1999) S tampfer and prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. Journal of the National Cancer Institute, 91, 620–625.
35. Manousos, O., Souglakos, J., Bosetti, C., Tzonou, A., Chatzidakis, V., Trichopoulos, D., Adami, H.O. & Mantzoros, C. (1999) IGF-I and IGF-II in relation to colorectal cancer. International Journal of Cancer, 83, 15–17.
36. Burroughs, K.D., Dunn, S.E., Barrett, J.C. & Taylor, J.A. (1999) Insulinlike growth factor-I: a key regulator of human cancer risk? Journal of National Cancer Institute, 91, 579–581.
37. el Atiq, F., Garrouste, F., Remacle-Bonnet, M., Sastre, B. & Pommier, G. (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. International Journal of Cancer, 57, 491–497.
38. Renehan, A.G., Zwahlen, M., Minder, C., O'Dwyer, S.T., Shalet, S.M. & Egger, M. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346–1353.
39. Baxter, R.C., Butt, A.J., Schedlich, L.J. & Martin, J.L. (2000) Antiproliferative and pro-apoptotic activities of insulin-like growth factor-binding protein-3. Growth Hormone and IGF Research, 10, S10–S11.
40. Gill, Z.P., Perks, C.M., Newcomb, P.V. & Holly, J.M. (1997) Insulinlike growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. Journal of Biological Chemistry, 272, 25602–25607.
41. Jenkins, P.J. & Besser, M. (2001) Clinical perspective: acromegaly and cancer: a problem. Journal of Clinical Endocrinology and Metabolism, 86, 2935–2941.
42. Renehan, A.G., O'Connell, J., O'Halloran, D., Shanahan, F., Potten, C.S., O'Dwyer, S.T. & Shalet, S.M. (2003) Acromegaly and colorectal cancer: a comprehensive review of epidemiology, biological mechanisms, and clinical implications. Hormone and Metabolic Research, 35, 712–725.
43. Melmed, S. (2001) Acromegaly and cancer: not a problem? Journal of Clinical Endocrinology and Metabolism, 86, 2929–2934.
44. Jenkins, P.J., Fairclough, P.D., Richards, T., Lowe, D.G., Monson, J., Grossman, A., Wass, J.A.H. & Besser, G.M. (1997) Acromegaly, colonic polyps and carcinoma. Clinical Endocrinology, 47, 17–22.
45. Renehan, A.G., Bhaskar, P., Painter, J.E., O'Dwyer, S.T., Haboubi, N., Ball, S.G. & Shalet, S.M. (2000) The prevalence and characteristics of colorectal neoplasia in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 3417–3424.
46. Jenkins, P.J., Frajese, V., Jones, A.-M., Camacho-Hubner, C., Lowe, D.G., Fairclough, P.D., Chew, S.L., Grossmann, A.B., Monson, J. & Besser, G.M. (2000) IGF-I and the development of colorectal neoplasia in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 3218–3221.
47. Cats, A., Dullaart, R.P., Kleibeuker, J.H., Kuipers, F., Sluiter, W.J., Hardonk, M.J. & de Vries, E.G. (1996) Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Research, 56, 523–526.
48. Orme, S.M., McNally, R.J., Cartwright, R.A. & Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism, 83, 2730– 2734.
49. Nabarro, J.D. (1987) Acromegaly. Clinical Endocrinology, 26, 481– 512.
50. Dunn, S.E., Ehrlich, M., Sharp, N.J., Reiss, K., Solomon, G., Hawkins, R., Baserga, R. & Barrett, J.C. (1998) A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Research, 58, 3353– 3361.
51. Adachi, Y., Lee, C.T., Coffee, K., Yamagata, N., Ohm, J.E., Park, K.H., Dikov, M.M., Nadaf, S.R., Arteaga, C.L. & Carbone, D.P. (2002) Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology, 123, 1191–1204.
52. Wen, B., Deutsch, E., Marangoni, E., Frascona, V., Maggiorella, L., Abdulkarim, B., Chavaudra, N. & Bourhis, J. (2001) Tyrphostin AG modulates radiosensitivity in human breast cancer cells. British Journal of Cancer, 85, 2017–2021.
53. Friend, K.E. (2001) Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Hormone and IGF Research, 11, S121–S123.
54. Maple, S., Fernandes, J., Khandwala, H., Scarlett, J.A., Davis, R.A., Flyvbjerg, A., et al. (2001) Pegvisomant inhibits tumor growth in a syngenic model of colon cancer metastasis. Proceedings of the 83rd American Endocrine Society, p1–218.

 

[Fa Seeshus]

you need to be very aware of any weird skin growths. the tanning + growth and or igf-1 will accelerate melanoma. a 37 y/o natural pro from my area (who used gh) died of melanoma that had spread through his body--eventually to his brain.

i know of two others who have had to get cancerous growths removed.

 

[guns123]

you need to be very aware of any weird skin growths. the tanning + growth and or igf-1 will accelerate melanoma. a 37 y/o natural pro from my area (who used gh) died of melanoma that had spread through his body--eventually to his brain.

i know of two others who have had to get cancerous growths removed.

so i guess you would advise against the use of melanotan2 at the same time as igf/gh.
tanning beds also?

 

[Fa Seeshus]

anything in moderation. this guy was sorta extreme: he always stayed very very lean (on GH) and tanned year round. plus he did not get a questionable growth looked at.

 

[finny]

anything in moderation. this guy was sorta extreme: he always stayed very very lean (on GH) and tanned year round. plus he did not get a questionable growth looked at.

What 'questionable skin growth' are we talking about?

 

[Fa Seeshus]

http://living.health.com/2008/04/23/how-to-spot-skin-cancer/